Literature DB >> 12576551

Tissue transglutaminase-induced aggregation of alpha-synuclein: Implications for Lewy body formation in Parkinson's disease and dementia with Lewy bodies.

Eunsung Junn1, Ruben D Ronchetti, Martha M Quezado, Soo-Youl Kim, M Maral Mouradian.   

Abstract

Proteinaceous aggregates containing alpha-synuclein represent a feature of neurodegenerative disorders such as Parkinson's disease, dementia with Lewy bodies, and multiple system atrophy. Despite extensive research, the mechanisms underlying alpha-synuclein aggregation remain elusive. Previously, tissue transglutaminase (tTGase) was found to contribute to the generation of aggregates by cross-linking pathogenic substrate proteins in Huntington's and Alzheimer's diseases. In this article, the role of tTGase in the formation of alpha-synuclein aggregates was investigated. Purified tTGase catalyzed alpha-synuclein cross-linking, leading to the formation of high molecular weight aggregates in vitro, and overexpression of tTGase resulted in the formation of detergent-insoluble alpha-synuclein aggregates in cellular models. Immunocytochemical studies demonstrated the presence of alpha-synuclein-positive cytoplasmic inclusions in 8% of tTGase-expressing cells. The formation of these aggregates was significantly augmented by the calcium ionophore and prevented by the inhibitor cystamine. Immunohistochemical studies on postmortem brain tissue confirmed the presence of transglutaminase-catalyzed epsilon (gamma-glutamyl)lysine cross-links in the halo of Lewy bodies in Parkinson's disease and dementia with Lewy bodies, colocalizing with alpha-synuclein. These findings, taken together, suggest that tTGase activity leads to alpha-synuclein aggregation to form Lewy bodies and perhaps contributes to neurodegeneration.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12576551      PMCID: PMC149956          DOI: 10.1073/pnas.0438021100

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  60 in total

1.  Therapeutic effects of cystamine in a murine model of Huntington's disease.

Authors:  Alpaslan Dedeoglu; James K Kubilus; Thomas M Jeitner; Samantha A Matson; Misha Bogdanov; Neil W Kowall; Wayne R Matson; Arthur J L Cooper; Rajiv R Ratan; M Flint Beal; Steven M Hersch; Robert J Ferrante
Journal:  J Neurosci       Date:  2002-10-15       Impact factor: 6.167

2.  Prolonged survival and decreased abnormal movements in transgenic model of Huntington disease, with administration of the transglutaminase inhibitor cystamine.

Authors:  Marcela V Karpuj; Mark W Becher; Joe E Springer; Dorothee Chabas; Sawsan Youssef; Rosetta Pedotti; Dennis Mitchell; Lawrence Steinman
Journal:  Nat Med       Date:  2002-02       Impact factor: 53.440

Review 3.  Biochemistry of transglutaminases and cross-linking in the skin.

Authors:  L L Peterson; J G Zettergren; K D Wuepper
Journal:  J Invest Dermatol       Date:  1983-07       Impact factor: 8.551

4.  Specificity of guinea pig liver transglutaminase for amine substrates.

Authors:  L Lorand; K N Parameswaran; P Stenberg; Y S Tong; P T Velasco; N A Jönsson; L Mikiver; P Moses
Journal:  Biochemistry       Date:  1979-05-01       Impact factor: 3.162

5.  Intron-exon swapping of transglutaminase mRNA and neuronal Tau aggregation in Alzheimer's disease.

Authors:  B A Citron; K S SantaCruz; P J Davies; B W Festoff
Journal:  J Biol Chem       Date:  2000-09-29       Impact factor: 5.157

6.  Increase in proliferative markers after inhibition of transglutaminase.

Authors:  P J Birckbichler; G R Orr; M K Patterson; E Conway; H A Carter
Journal:  Proc Natl Acad Sci U S A       Date:  1981-08       Impact factor: 11.205

7.  Brain transglutaminase: in vitro crosslinking of human neurofilament proteins into insoluble polymers.

Authors:  D J Selkoe; C Abraham; Y Ihara
Journal:  Proc Natl Acad Sci U S A       Date:  1982-10       Impact factor: 11.205

8.  Parkin accumulation in aggresomes due to proteasome impairment.

Authors:  Eunsung Junn; Sang Seop Lee; Unsun T Suhr; M Maral Mouradian
Journal:  J Biol Chem       Date:  2002-10-02       Impact factor: 5.157

9.  Identification of a guanosine triphosphate-binding site on guinea pig liver transglutaminase. Role of GTP and calcium ions in modulating activity.

Authors:  K E Achyuthan; C S Greenberg
Journal:  J Biol Chem       Date:  1987-02-05       Impact factor: 5.157

10.  Tissue transglutaminase differentially modulates apoptosis in a stimuli-dependent manner.

Authors:  Janusz Tucholski; Gail V W Johnson
Journal:  J Neurochem       Date:  2002-05       Impact factor: 5.372

View more
  66 in total

Review 1.  γ-Glutamylamines and neurodegenerative diseases.

Authors:  Thomas M Jeitner; Kevin Battaile; Arthur J L Cooper
Journal:  Amino Acids       Date:  2012-03-10       Impact factor: 3.520

Review 2.  The Lewy body in Parkinson's disease and related neurodegenerative disorders.

Authors:  Koichi Wakabayashi; Kunikazu Tanji; Saori Odagiri; Yasuo Miki; Fumiaki Mori; Hitoshi Takahashi
Journal:  Mol Neurobiol       Date:  2012-05-24       Impact factor: 5.590

3.  MicroRNA-7 facilitates the degradation of alpha-synuclein and its aggregates by promoting autophagy.

Authors:  Doo Chul Choi; Myungsik Yoo; Savan Kabaria; Eunsung Junn
Journal:  Neurosci Lett       Date:  2018-05-05       Impact factor: 3.046

4.  Two isoforms of tissue transglutaminase mediate opposing cellular fates.

Authors:  Marc A Antonyak; Jaclyn M Jansen; Allison M Miller; Thi K Ly; Makoto Endo; Richard A Cerione
Journal:  Proc Natl Acad Sci U S A       Date:  2006-11-20       Impact factor: 11.205

5.  Pharmacokinetics of cysteamine bitartrate following gastrointestinal infusion.

Authors:  Meredith C Fidler; Bruce A Barshop; Jon A Gangoiti; Reena Deutsch; Michael Martin; Jerry A Schneider; Ranjan Dohil
Journal:  Br J Clin Pharmacol       Date:  2007-01       Impact factor: 4.335

Review 6.  The role of lipids in α-synuclein misfolding and neurotoxicity.

Authors:  Cathryn L Ugalde; Victoria A Lawson; David I Finkelstein; Andrew F Hill
Journal:  J Biol Chem       Date:  2019-05-07       Impact factor: 5.157

7.  Tissue transglutaminase can be involved in airway inflammation of toluene diisocyanate-induced occupational asthma.

Authors:  Gyu-Young Hur; Sung-Ho Kim; Sang Myun Park; Young-Min Ye; Cheol-Woo Kim; An-Soo Jang; Choon-Sik Park; Chein Soo Hong; Hae-Sim Park
Journal:  J Clin Immunol       Date:  2009-06-27       Impact factor: 8.317

8.  Mitochondrial aconitase is a transglutaminase 2 substrate: transglutamination is a probable mechanism contributing to high-molecular-weight aggregates of aconitase and loss of aconitase activity in Huntington disease brain.

Authors:  Soo-Youl Kim; Lyuben Marekov; Parvesh Bubber; Susan E Browne; Irina Stavrovskaya; Jongmin Lee; Peter M Steinert; John P Blass; M Flint Beal; Gary E Gibson; Arthur J L Cooper
Journal:  Neurochem Res       Date:  2005-10       Impact factor: 3.996

9.  Repression of alpha-synuclein expression and toxicity by microRNA-7.

Authors:  Eunsung Junn; Kang-Woo Lee; Byeong Seon Jeong; Teresa W Chan; Joo-Young Im; M Maral Mouradian
Journal:  Proc Natl Acad Sci U S A       Date:  2009-07-23       Impact factor: 11.205

Review 10.  Neurochemical approaches in the laboratory diagnosis of Parkinson and Parkinson dementia syndromes: a review.

Authors:  Sarah Jesse; Petra Steinacker; Stefan Lehnert; Frank Gillardon; Bastian Hengerer; Markus Otto
Journal:  CNS Neurosci Ther       Date:  2009-03-09       Impact factor: 5.243

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.